It also explains why so many field teams spend their time executing plans that no longer resemble clinical reality by the time they reach a physician’s office.
The more accurate picture is less flattering: office-based Medical Affairs defines the scientific direction, while Field Medical tests whether that direction survives contact with investigators, KOLs, healthcare systems and actual evidence gaps. One side builds the narrative architecture; the other discovers which walls are load-bearing. Treating the two as interchangeable is not alignment. It is organisational wishful thinking.
I have watched this distinction get blurred in launch plans, operating models and polished capability decks. The result is usually predictable: headquarters celebrates consistency, the field reports friction, and everyone quietly agrees that the problem is “engagement.” It is rarely engagement. More often, it is a failure to connect strategic intent with field intelligence.
The real question in MSL field medical strategy vs medical affairs office strategy is not which side owns the truth. It is how the two functions create a scientific operating model in which strategy can change when the evidence, practice environment or stakeholder priorities demand it.
The strategic divide is real — and useful
Office-based Medical Affairs and Field Medical have different jobs. That is not a weakness to be engineered away. It is the reason the model can work.
Medical Directors and headquarters Medical Affairs leaders set the overall non-promotional scientific vision. They shape the medical narrative, define communication priorities and coordinate plans across the product lifecycle. This includes decisions around evidence generation, scientific communications, medical education, investigator-initiated research and the questions the organisation needs to answer before and after launch.
MSLs operate closer to the clinical environment. Their work involves direct engagement with KOLs and other healthcare professionals, scientific exchange, congress activity, presentations and systematic collection of field insights. They translate strategic priorities into conversations that make sense in a specific market, disease area and healthcare system.
That translation is not a basic delivery function. A scientific narrative may be coherent in a headquarters meeting and still fail in the field because it assumes:
- the clinical question has already been settled;
- the relevant evidence is available in a usable form;
- local treatment pathways resemble the global strategy;
- KOL priorities remain stable throughout development;
- the organisation understands the practical barriers to adoption;
- the message is sufficiently precise for an expert audience.
These assumptions are where strategy begins to lose oxygen.
The Medical Affairs office has the advantage of breadth. It can see the full programme, coordinate cross-functional input and maintain consistency across regions. The field has the advantage of proximity. An MSL hears hesitation before it appears in a formal report, notices when a supposedly important endpoint is not the question clinicians are asking, and identifies where a publication plan is scientifically elegant but operationally irrelevant.
Neither perspective is sufficient on its own.
Headquarters defines the scientific question; the field discovers whether anyone outside headquarters thinks it is the right question.
The numbers reinforce the practical distinction. According to Medical Science Liaison Society data, 95% of MSLs attend medical congresses and manage KOL relationships. Ninety-three percent educate KOLs and healthcare professionals, while 92% deliver scientific presentations. These are not incidental activities attached to a strategy created elsewhere. They are the mechanism through which a strategy meets the scientific community.
Medical Advisor and MSL are not interchangeable titles
The division becomes particularly muddled in global operating models, where the same title can mean different things in different markets. In Europe and the wider EMEA region, a Medical Advisor commonly holds an in-house, strategy-oriented role under Medical Director leadership, with roughly 70% of time spent in the office. An MSL typically maintains a more field-based role, with around 80% of time spent in the field.
The exact split varies by company, therapy area and geography. The underlying distinction is more durable:
| Dimension | Office-based Medical Affairs | Field Medical |
|---|---|---|
| Primary orientation | Strategic planning and scientific governance | External scientific exchange and field execution |
| Typical stakeholders | Internal leadership, cross-functional teams, evidence and communications groups | KOLs, investigators, HCPs and scientific communities |
| Core contribution | Defines medical priorities, narratives and evidence plans | Tests priorities in practice and gathers contextual insight |
| Time horizon | Portfolio, lifecycle and programme planning | Immediate clinical questions linked to longer-term signals |
| Main risk | Strategy becomes detached from current clinical reality | Local activity becomes disconnected from enterprise priorities |
| Strongest asset | Coordination and strategic coherence | Proximity, credibility and unfiltered field intelligence |
The table is not a licence to build two sealed departments. It is a reminder that alignment requires translation between different kinds of work. A headquarters team should not expect the field to function as a remote communications channel. An MSL team should not treat every local request as a new strategic direction.
Alignment is the discipline of deciding what must remain consistent and what must remain adaptable.
Pre-launch engagement is not an optional courtesy
Another persistent misconception is that serious field medical engagement begins at launch, when products are approved and the organisation finally has something to discuss. That idea has the useful advantage of being simple. It is also late.
A ZS study found that 82% of KOLs prefer MSL interactions to begin before launch, with most preferring engagement during Phase III clinical development. That preference makes clinical sense. By the time a product reaches launch, many of the questions that determine its reception have already formed:
- Which patient population is most clinically relevant?
- How does the emerging evidence compare with existing practice?
- Which endpoints matter to specialists in routine care?
- Where are the evidence gaps likely to affect confidence?
- What would make a future study genuinely useful rather than merely publishable?
- Which aspects of the disease area are poorly understood outside specialist centres?
These are not questions that should be saved for a launch-readiness workshop.
Early engagement also changes the quality of the relationship. A pre-launch MSL conversation can focus on scientific uncertainty rather than product positioning. The exchange is less likely to be interpreted as a disguised commercial call because the work is anchored in evidence development, disease understanding and unmet clinical questions. That is precisely the territory in which Medical Affairs should be strongest.
The practical problem is that early engagement requires the office and field to agree on what is known, what is not known and what must not be overstated. Marketing language is built to close ambiguity. Medical Affairs has to preserve it when the evidence remains incomplete. Those are very different instincts.
An office strategy that reaches the field as a polished, final narrative leaves little room for genuine scientific exchange. An MSL strategy that ignores the broader evidence plan risks producing a collection of interesting conversations with no organisational memory.
The pre-launch test
A useful pre-launch alignment test is not whether the field can repeat the medical plan. It is whether MSLs can explain:
1. Which scientific questions the organisation is actively trying to answer.
2. Which questions remain unresolved and can be discussed openly.
3. What evidence currently supports the central narrative.
4. Where the evidence is limited, indirect or still emerging.
5. How field insights will influence future evidence generation or communications.
6. Which requests belong in Medical Information, clinical development, publications or another function.
If the answer to each question is a slide reference, the strategy is probably not operational yet. Slides are evidence that a meeting happened. They are not evidence that the field can work intelligently.
The feedback loop must produce decisions, not just reports
Most organisations claim to value field insights. Many even have a formal process for collecting them. The less comfortable question is what happens next.
Field intelligence becomes strategically useful only when it changes a decision, clarifies a priority or prevents an avoidable mistake. Otherwise, it is a well-formatted archive of concerns that no one had time to act on.
The feedback loop between MSLs and office-based Medical Affairs has four practical stages.
1. Capture the observation without flattening it
An MSL may hear that a study endpoint is viewed as less meaningful than expected, that a subgroup analysis is generating confusion, or that a guideline change has altered clinical priorities. These observations need context. A field insight stripped of the question, stakeholder type and clinical setting becomes little more than a sentiment score.
The quality of the input matters. “KOLs are interested in real-world evidence” is too vague to guide action. A useful insight identifies what decision the evidence would support, which population is affected and what current evidence is insufficient.
2. Separate signal from local preference
Not every request from a prominent specialist is a strategic signal. KOL engagement is valuable partly because it exposes differences in clinical thinking, but difference is not automatically direction.
The office team has to assess whether an insight reflects:
- a broad evidence gap across the disease area;
- a regional practice pattern;
- a methodological concern;
- a communication failure;
- a single stakeholder’s research interest;
- a question that belongs to another function.
This is where strategic judgement matters. The field should not be asked to decide enterprise priorities alone, and headquarters should not dismiss local variation merely because it complicates the global narrative.
3. Translate the insight into an owner and a decision
A feedback loop without ownership is an internal echo chamber. Insights should lead to a defined response: revise a scientific communication, commission further analysis, adjust an advisory board agenda, refine investigator-initiated study priorities, update medical information content or escalate a genuine safety and evidence concern.
The response does not always need to be “yes.” A considered “not now,” with a rationale, is more useful than silence. It tells the field that the insight was evaluated rather than swallowed by a central repository.
4. Return the outcome to the field
The loop closes when MSLs can see how their input affected the programme — or why it did not. This does not require a long internal memo. It requires enough explanation for the field to understand the decision and continue the conversation credibly.
Without that return path, MSLs learn to stop reporting difficult insights. They give the organisation what is easiest to process. That is how alignment becomes optics.
A field insight that never changes a decision is not intelligence. It is administrative exhaust.
Regulatory independence is part of the operating model
The division between Medical Affairs and commercial functions is not a decorative line in an organisational chart. It is a scientific and compliance requirement.
The EFPIA Code of Practice and the FSA Code require separation between scientific Medical Affairs activities and commercial sales functions. MSL compensation and reporting lines should not be tied to sales targets. This is not an inconvenience imposed on an otherwise efficient business model. It protects the credibility of the exchange.
The distinction matters particularly when leaders discuss “alignment.” Alignment with what? If the word quietly means alignment with revenue objectives, the organisation has already crossed the conceptual line it claims to respect.
Medical Affairs can align with the broader product lifecycle without becoming a commercial instrument. It can support launch readiness through evidence planning, medical education, insight generation and appropriate scientific communication. It can identify where clinicians need clearer information. It can help the organisation understand how a therapy may fit into clinical practice. None of this requires MSLs to carry a sales quota or to report into a commercial chain of command.
The language used internally matters. “Customer targeting,” “conversion,” “account prioritisation” and “opportunity development” may be familiar commercial terms, but they distort the role when applied to scientific exchange. The field medical team is not a softer sales force. It is a distinct function with a different purpose and a different standard of credibility.
What independence should look like in practice
Independence is easier to defend when the operating model makes it visible:
- MSL objectives focus on scientific exchange, insight quality, education and stakeholder engagement rather than sales outcomes.
- Field priorities are set through medical strategy, not commercial account plans.
- Medical and commercial teams may coordinate where appropriate, but they do not collapse their roles.
- Scientific materials are governed through medical and compliance processes.
- Field insights are assessed for evidence value, not merely for commercial opportunity.
- Leadership protects the MSL’s ability to acknowledge uncertainty and say that evidence is insufficient.
The last point is often the hardest. An organisation may preserve formal reporting independence while subtly penalising inconvenient scientific conversations. The chart remains compliant; the culture does not.
Measuring alignment without rewarding theatre
The 2024 ZS Medical Affairs Outlook Report found that only 19% of surveyed pharmaceutical companies described their Medical Affairs function as best in class. That figure should make leaders suspicious of activity-based dashboards. If most organisations can report a large volume of meetings, congresses and presentations while relatively few consider themselves excellent, the missing ingredient is unlikely to be more activity.
MSL performance naturally includes tangible measures. Congress attendance, KOL engagement, education and scientific presentations are legitimate parts of the role. But volume does not demonstrate strategic impact. A team can complete every planned interaction and still fail to identify the evidence question that matters most.
A stronger measurement approach examines the quality and consequences of the work:
Strategic coherence
Can the field explain the medical priorities in a way that is scientifically accurate and clinically useful? Do local plans connect to the broader evidence and communication strategy without becoming rigid replicas of it?
Insight quality
Are field insights specific, contextual and actionable? Do they distinguish a recurring evidence gap from a one-off preference? Are they connected to potential decisions?
Responsiveness
How quickly and clearly does the office-based team respond to material field signals? Does the organisation visibly adapt its communication, evidence or education plans when warranted?
Stakeholder value
Do KOLs receive meaningful scientific exchange rather than repetitive content delivery? Is engagement beginning early enough to support genuine dialogue during clinical development?
Lifecycle contribution
Does the field help the organisation understand changing clinical practice, emerging evidence and implementation barriers across the product lifecycle? Medical Affairs should not disappear into launch preparation and reappear only when a new issue reaches the inbox.
Independence
Can the function demonstrate that its priorities, objectives and interactions remain separate from sales incentives? Independence should be observable in governance, not merely repeated in training modules.
The aim is not to eliminate activity metrics. It is to put them in their proper place. A meeting count is a record of motion. It does not tell you whether the organisation moved in the right direction.
Building an operating rhythm that can survive reality
Alignment is often treated as a workshop problem: gather leadership, produce a framework, agree on terminology and circulate the deck. Then the organisation waits for alignment to occur by administrative osmosis.
It will not.
The relationship between office strategy and field medical execution needs a repeatable operating rhythm. That rhythm should include structured insight review, clear ownership, rapid escalation for material scientific issues and planned opportunities to revise priorities. It should also allow regional and therapeutic-area differences to remain visible rather than forcing every signal into a global template.
A practical model usually includes:
1. A shared medical strategy that defines the non-promotional scientific priorities.
The strategy should distinguish settled evidence from open questions. If everything is presented as equally certain, the field cannot have an honest scientific conversation.
2. Field plans that translate priorities rather than copy them.
MSL objectives should reflect the local stakeholder landscape, clinical practice and evidence environment while remaining connected to the central strategy.
3. A consistent taxonomy for field insights.
Without common definitions, one region reports an evidence gap while another reports an engagement opportunity, and leadership compares labels instead of substance.
4. Regular medical insight governance.
The purpose is not to review every interaction. It is to identify patterns, decide what requires action and document the rationale when the organisation chooses not to act.
5. Feedback to the field.
MSLs should know how insight informs publications, evidence generation, medical information, education or future engagement. Otherwise, the system trains them to report safely rather than honestly.
6. Independent leadership and incentives.
The function must be protected from commercial pressure not only in policy, but in targets, reporting lines and career expectations.
This is not an especially glamorous model. It does not produce a dramatic transformation narrative for a leadership off-site. It does something more useful: it makes the organisation harder to surprise.
The comparison that actually matters
The debate over field medical excellence versus internal Medical Affairs strategy is sometimes framed as a contest between local agility and global consistency. That is an unhelpful comparison. The two are not competing products.
Office strategy without field intelligence becomes polished irrelevance. Field activity without office strategy becomes fragmented responsiveness — busy, credible in places, and strategically incoherent at scale.
The stronger model treats the functions as different instruments in the same scientific system. Headquarters sets the direction and holds the organisation to a coherent evidence standard. The field tests assumptions, builds credible relationships, surfaces uncertainty and brings back information that cannot be generated in a conference room. The system improves only when both sides are allowed to do their actual jobs.
The strategic mistake is not having a divide. The mistake is pretending the divide does not exist.
In my experience, the most reliable test is brutally simple: ask an MSL what the current medical priority is, ask a Medical Director what the field is hearing, and compare the answers. If they differ, do not immediately blame communication. The difference may be the most important piece of information the organisation has received.
The answer is not another alignment slogan. It is a functioning loop: strategy moves to the field, field reality moves back to strategy, and both are revised when the evidence demands it. That is how Medical Affairs earns influence — not by sounding aligned, but by being scientifically useful when the plan meets reality.